SLDB Stock Forecast 2025-2026
Distance to SLDB Price Targets
SLDB Price Momentum
10 Quality Stocks Worth Considering Now
Researching Solid Biosciences (SLDB) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on SLDB and similar high-potential opportunities.
Latest SLDB Stock Price Targets & Analyst Predictions
Based on our analysis of 18 Wall Street analysts, SLDB has a bullish consensus with a median price target of $16.00 (ranging from $11.00 to $20.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $4.48, the median forecast implies a 257.5% upside. This outlook is supported by 12 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Arthur He at HC Wainwright & Co., projecting a 346.9% upside. Conversely, the most conservative target is provided by Anupam Rama at JP Morgan, suggesting a 145.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SLDB Analyst Ratings
SLDB Price Target Range
Latest SLDB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SLDB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 13, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $11.00 |
| Mar 10, 2025 | HC Wainwright & Co. | Arthur He | Buy | Maintains | $20.00 |
| Mar 7, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $16.00 |
| Mar 7, 2025 | Citizens Capital Markets | Silvan Tuerkcan | Market Outperform | Reiterates | $15.00 |
| Feb 19, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $16.00 |
| Jan 13, 2025 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $16.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $16.00 |
| Jan 8, 2025 | Truist Securities | Joon Lee | Buy | Initiates | $16.00 |
| Dec 13, 2024 | Wedbush | Laura Chico | Outperform | Initiates | $16.00 |
| Dec 12, 2024 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $16.00 |
| Dec 12, 2024 | HC Wainwright& Co. | Buy | Reiterates | $0.00 | |
| Dec 10, 2024 | JMP Securities | Silvan Tuerkcan | Market Outperform | Initiates | $15.00 |
| Nov 12, 2024 | JP Morgan | Anupam Rama | Overweight | Maintains | $12.00 |
| Nov 11, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $15.00 |
| Nov 7, 2024 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $16.00 |
| Aug 14, 2024 | Barclays | Gena Wang | Overweight | Maintains | $15.00 |
| Aug 14, 2024 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $16.00 |
| Jul 15, 2024 | JP Morgan | Anupam Rama | Overweight | Upgrade | $15.00 |
| Jun 24, 2024 | Leerink Partners | Joseph Schwartz | Outperform | Upgrade | $12.00 |
| Jun 21, 2024 | Piper Sandler | Biren Amin | Overweight | Reiterates | $20.00 |
Solid Biosciences Inc. (SLDB) Competitors
The following stocks are similar to Solid Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Solid Biosciences Inc. (SLDB) Financial Data
Solid Biosciences Inc. has a market capitalization of $370.42M with a P/E ratio of 0.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -94.6%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Solid Biosciences Inc. (SLDB) Business Model
About Solid Biosciences Inc.
Develops therapies for Duchenne muscular dystrophy.
The company focuses on innovative gene therapies to restore functional dystrophin protein in muscle cells of patients with Duchenne muscular dystrophy (DMD). It generates revenue through the development and commercialization of its therapeutic pipeline, which is advanced through scientific research and clinical trials, supported by proprietary technologies and strategic partnerships.
Solid Biosciences operates within the biopharmaceutical industry, targeting rare diseases and genetic disorders. The company's efforts address a significant unmet medical need in the DMD community, with the potential to transform patient outcomes and contribute to advancements in the industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
100
CEO
Mr. Alexander G. Cumbo
Country
United States
IPO Year
2018
Website
www.solidbio.comSolid Biosciences Inc. (SLDB) Latest News & Analysis
Solid Biosciences Inc. (Nasdaq: SLDB) will present data from its Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, a gene therapy for Duchenne muscular dystrophy, at the MDA Conference on March 16-19, 2025.
Solid Biosciences' presentation of trial data for SGT-003 could indicate progress in treating Duchenne muscular dystrophy, influencing stock performance and investor sentiment in biotech.
Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
19 days agoThe INSPIRE DUCHENNE trial reported positive initial data for SGT-003, a Duchenne gene therapy. The company plans to seek FDA accelerated approval pathways in mid-2025.
Positive trial results for SGT-003 indicate potential for accelerated FDA approval, which could significantly impact the company’s stock value and market position in Duchenne treatment.
Solid Biosciences Inc. (Nasdaq: SLDB) will participate in upcoming investor conferences, focusing on its development of precision genetic medicines for neuromuscular and cardiac diseases.
Solid Biosciences' participation in investor conferences signals potential growth and visibility, which may attract interest and influence stock performance in the biotech sector.
Solid Biosciences stock increased by 60% in a month following the announcement of positive initial data from its phase I/II DMD study of SGT-003.
The 60% stock surge reflects strong market confidence in Solid Biosciences following promising clinical trial results, potentially enhancing its valuation and attracting more investment.
Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade
18 days agoWall Street analysts project a 198.2% upside for Solid Biosciences (SLDB), supported by positive earnings estimate revisions.
A 198.2% upside in price targets suggests strong growth potential for Solid Biosciences (SLDB), while positive earnings estimates may boost investor confidence and stock performance.
Solid Biosciences Inc. (Nasdaq: SLDB) announced the grant of 11,950 restricted stock units to a newly hired employee, indicating ongoing expansion in their workforce.
The grant of RSUs to a new employee signals Solid Biosciences' commitment to attracting talent, which can enhance innovation and drive growth, impacting future stock performance.
Frequently Asked Questions About SLDB Stock
What is Solid Biosciences Inc.'s (SLDB) stock forecast for 2025?
Based on our analysis of 18 Wall Street analysts, Solid Biosciences Inc. (SLDB) has a median price target of $16.00. The highest price target is $20.00 and the lowest is $11.00.
Is SLDB stock a good investment in 2025?
According to current analyst ratings, SLDB has 12 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.48. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SLDB stock?
Wall Street analysts predict SLDB stock could reach $16.00 in the next 12 months. This represents a 257.5% increase from the current price of $4.48. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Solid Biosciences Inc.'s business model?
The company focuses on innovative gene therapies to restore functional dystrophin protein in muscle cells of patients with Duchenne muscular dystrophy (DMD). It generates revenue through the development and commercialization of its therapeutic pipeline, which is advanced through scientific research and clinical trials, supported by proprietary technologies and strategic partnerships.
What is the highest forecasted price for SLDB Solid Biosciences Inc.?
The highest price target for SLDB is $20.00 from Arthur He at HC Wainwright & Co., which represents a 346.9% increase from the current price of $4.48.
What is the lowest forecasted price for SLDB Solid Biosciences Inc.?
The lowest price target for SLDB is $11.00 from Anupam Rama at JP Morgan, which represents a 145.8% increase from the current price of $4.48.
What is the overall SLDB consensus from analysts for Solid Biosciences Inc.?
The overall analyst consensus for SLDB is bullish. Out of 18 Wall Street analysts, 12 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $16.00.
How accurate are SLDB stock price projections?
Stock price projections, including those for Solid Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
